Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Park Therapeutics is developing a unique, first-in-class, investigational NCE for the treatment of pain which is Phase III-ready. With the acquisition, Tris owns worldwide rights and all accompanying intellectual property for cebranopadol.
Lead Product(s): Cebranopadol
Therapeutic Area: Neurology Product Name: PRK-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tris Pharma Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 29, 2021